Tango Therapeutics Inc (TNGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tango Therapeutics Inc (TNGX) has a cash flow conversion efficiency ratio of -0.193x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.95 Million) by net assets ($160.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tango Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Tango Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Tango Therapeutics Inc for a breakdown of total debt and financial obligations.
Tango Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tango Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greif Inc
NYSE:GEF-B
|
-0.008x |
|
Inner Mongolia Lantai Industrial Co Ltd
SHG:600328
|
-0.009x |
|
No Va Land Investment Group Corp
VN:NVL
|
0.053x |
|
BitVentures Limited
NASDAQ:BVC
|
N/A |
|
Bursa Malaysia Bhd
KLSE:1818
|
0.108x |
|
Guizhou Panjiang Refined Coal Co Ltd
SHG:600395
|
0.025x |
|
Borusan Mannesmann Boru Sanayi ve Ticaret AS
IS:BRSAN
|
0.011x |
|
Hamburger Hafen und Logistik Aktiengesellschaft
F:HHFA
|
0.101x |
Annual Cash Flow Conversion Efficiency for Tango Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tango Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Tango Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $199.52 Million | $-131.50 Million | -0.659x | -41.40% |
| 2023-12-31 | $253.11 Million | $-117.98 Million | -0.466x | -6.61% |
| 2022-12-31 | $249.48 Million | $-109.08 Million | -0.437x | -153.22% |
| 2021-12-31 | $344.75 Million | $-59.53 Million | -0.173x | -109.51% |
| 2020-12-31 | $38.60 Million | $70.07 Million | 1.815x | +157.86% |
| 2019-12-31 | $7.91 Million | $-24.80 Million | -3.138x | -- |
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more